SCHEMBL22843451

SCHEMBL22843451

CN(CP)S(=O)(=O)c1ccc(Nc2ncc(C(F)(F)F)cn2)c(-c2cn(C)cn2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TEAD1 P28347 3/20 0.54
▸ YAP1 P46937 1/20 0.54
▸ TLR2 O60603 1/20 0.35
▸ TLR1 Q15399 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ LMNA P02545 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ EGFR P00533 1/20 0.32
▸ FGFR1 P11362 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ LRRK2 Q5S007 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22843430 0.89 TEAD1 (0.54) TEAD1YAP1TLR2TLR1L3MBTL1
SCHEMBL22843403 0.86 TEAD1 (0.52) TEAD1YAP1TLR2TLR1KDM4E
SCHEMBL29438921 0.86 TEAD1 (0.49) TEAD1YAP1KDM4EMEN1KMT2A
SCHEMBL22718104 0.86 TEAD1 (0.49) TEAD1YAP1KDM4EMEN1KMT2A
SCHEMBL22843408 0.85 TEAD1 (0.56) TEAD1YAP1TLR2TLR1L3MBTL1
SCHEMBL22843425 0.84 TEAD1 (0.49) TEAD1YAP1TLR2TLR1L3MBTL1
SCHEMBL22843440 0.83 TEAD1 (0.47) TEAD1YAP1KDM4EMEN1KMT2A
SCHEMBL22718301 0.83 TEAD1 (0.76) TEAD1YAP1TLR2TLR1L3MBTL1
SCHEMBL29438928 0.83 TEAD1 (0.76) TEAD1YAP1TLR2TLR1L3MBTL1
SCHEMBL22843472 0.81 KMT2A (0.38) L3MBTL1PTGS2KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760728-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2023-09-19 — — US disclosed
US-11274082-B2 Tead inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-03-15 — — US disclosed
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF THE EHE FOUNDATION 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11274082-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885TLR2 4827/4885
US-11760728-B2 Tead inhibitors and uses thereof TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885TLR2 4827/4885
US-20200407327-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 TEAD1 4/4885YAP1 111/4885TLR2 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback